Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Antiviral Drugs Advisory Committee
The Antiviral Drugs Advisory Committee will discuss new drug application (NDA) 021-814, proposed tradename Aptivus (Tipranavir) 250 milligrams (mg) capsules, Boehringer Ingelheim Pharmaceuticals, Inc., indicated for the treatment of patients with HIV.
Call to Order and Opening Remarks
Introduction of Committee
Conflict of Interest Statement Anuja Patel, M.P.H.
Executive Secretary, FDA
Overview of Issues
Open Public Hearing
Discussion and Questions to the Committee